Treatment of pediatric cutaneous leishmaniasis with liposomal amphotericin B

Abstract

The use of liposomal amphotericin B (L-AmB) in the treatment of cutaneous leishmaniasis (CL) is increasing. However, few data are available regarding the efficacy and safety of L-AmB in pediatric CL patients. Our aim in this study is to evaluate the efficacy and safety of L-AmB in pediatric CL patients. Pediatric patients admitted to a tertiary training and research hospital in a hyperendemic region for CL between January 2019 and May 2021 and receiving L-AmB therapy for CL were included in this retrospective study. L-AmB treatment was administered as 3 mg/kg for 5 consecutive days and on the 10th day, in a total of 6 doses (18 mg/kg total dose). A total of 52 pediatric patients who received L-AmB therapy for CL were included in the study.

Sistemik Antimon ile Tedavi Edilen Kutanöz Leishmaniasis Tanılı Hastaların Klinik Özellikleri ve Tedavi Yanıtları

“…Çalışmamızda da lezyonlar literatür verilerine benzer şekilde en sık yüz bölgesinde bulunmaktaydı ve en sık nodüloülseratif tip lezyonlar görülmekteydi. KL de lezyonlar tek olabileceği gibi aynı anda çok sayıda lezyon da bulunabilmektedir (2,11,14). Türkiye' de yapılan bir çalışmada KL tanılı hastaların büyük bir kısmında (%71) tek lezyon görüldüğü belirtilmiştir (15).…”

Cutaneous leishmaniasis of the eyelids: Retrospective evaluation of 18 patients

“…Treatment should be started immediately in order to prevent the development of complications in lesions located on the eyelid. Agents such as intralesional (IL) MA, systemic MA, IL, and systemic Amphotericin B, cryotherapy, and topical paromomycin can be used in the treatment [ 1 , 3 , 5 , 8 , 17 , 30 – 32 ]. Durdu et al [ 9 ] treated 59 CL patients with involvement around the eyelid as follows: 50 by IL MA, 2 by IL MA and cryotherapy, 5 by systemic MA, and 2 by cryotherapy alone.…”